



Clinical Status 2006

Clinical Status 2006 -

Avantogen Oncology Inc. (AVTO), Los Angeles, Calif.

Bioaccelerate Holdings Inc. (BACL), New York, N.Y.

RESprotect GmbH, Dresden, Germany



- * Product: RP101
- * Business: Cancer
- * Molecular target: STAT3 mRNA; Apex gene
- * Description: Inhibits induced chemoresistance and enhances chemosensitivity
- * Indication: Treat advanced pancreatic cancer
- * Endpoint: NA
- * Status: Interim Phase I data
- * Milestone: Submit IND (4Q06); start Phase II (early 2007)

Interim data from an open-label Phase I trial in 22 patients showed that RP101 plus gemcitabine led to survival rates of 68% and 39% at 6 and 12 months, respectively. The estimated median survival was 9.3 months.

- * Product: RP101
- * Business: Cancer
- * Molecular target: STAT3 mRNA; Apex gene
- * Description: Inhibits induced chemoresistance and enhances chemosensitivity
- * Indication: Treat advanced pancreatic cancer
- * Endpoint: NA
- * Status: Phase II start
- * Milestone: Start Phase II (early 2007)

By early next year, AVTO will begin a Phase II trial comparing 750 mg daily of RP101 plus gemcitabine to gemcitabine plus placebo.



RESprotect
Prevention of Chemoresistance

[download original PDF document](#)